EUCI Stock Overview
Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Eurocine Vaccines AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.055 |
| 52 Week High | kr1.39 |
| 52 Week Low | kr0.015 |
| Beta | 2.16 |
| 1 Month Change | 231.33% |
| 3 Month Change | 89.66% |
| 1 Year Change | -95.00% |
| 3 Year Change | -99.26% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| EUCI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -40.0% | 2.5% | -0.7% |
| 1Y | -95.0% | -3.4% | 4.4% |
Price Volatility
| EUCI volatility | |
|---|---|
| EUCI Average Weekly Movement | 60.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Volatility Over Time: EUCI's weekly volatility has increased from 38% to 60% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3 | Hans Arwidsson | www.eurocine-vaccines.com |
Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden. The company is developing Herpes Simplex Virus type 2 and Chlamydia vaccines. Eurocine Vaccines AB (publ) was incorporated in 1999 and is based in Solna, Sweden.
Eurocine Vaccines AB (publ) Fundamentals Summary
| EUCI fundamental statistics | |
|---|---|
| Market cap | kr10.55m |
| Earnings (TTM) | -kr15.06m |
| Revenue (TTM) | kr7.00k |
1,508x
P/S Ratio-0.7x
P/E RatioIs EUCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUCI income statement (TTM) | |
|---|---|
| Revenue | kr7.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr7.00k |
| Other Expenses | kr15.07m |
| Earnings | -kr15.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.078 |
| Gross Margin | 100.00% |
| Net Profit Margin | -215,114.29% |
| Debt/Equity Ratio | 0% |
How did EUCI perform over the long term?
See historical performance and comparison